683 Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

683 Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,000	Closed	-$95K	–	309
2022 Q3	$95K	Sell	10,000 -10,686	-52%	-$140K	0.01%	158
2022 Q2	$248K	Buy	20,686 +10,686	+107%	+$112K	0.02%	167
2022 Q1	$131K	Hold	10,000	–	–	0.01%	284
2021 Q4	$176K	Sell	10,000 -10,000	-50%	-$200K	0.01%	286
2021 Q3	$434K	Buy	+20,000	New	+$510K	0.02%	161
2019 Q3	–	Sell	-35,899	Closed	-$4.27M	–	152
2019 Q2	$4.27M	Sell	35,899 -340	-0.9%	-$28.1K	0.39%	56
2019 Q1	$1.9M	Hold	36,239	–	–	0.17%	75
2018 Q4	$1.14M	Buy	36,239 +33,385	+1,170%	+$1.36M	0.07%	104
2018 Q3	$173K	Buy	+2,854	New	+$160K	0.01%	129
2018 Q1	–	Sell	-55,000	Closed	-$1.93M	–	145
2017 Q4	$1.93M	Hold	55,000	–	–	0.16%	90
2017 Q3	$2.01M	Buy	55,000 +12,500	+29%	+$347K	0.21%	77
2017 Q2	$1.06M	Buy	42,500 +7,500	+21%	+$205K	0.16%	77
2017 Q1	$945K	Buy	35,000 +10,000	+40%	+$284K	0.15%	78
2016 Q4	$725K	Buy	+25,000	New	+$817K	0.05%	94

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

683 Capital Management's ADVM Position: Q4 2022 in Review

683 Capital Management sold out of Adverum Biotechnologies (ADVM) in Q4 2022, closing a stake of 10,000 shares — an estimated $95K sold.

683 Capital Management first reported a position in ADVM in Q4 2016 and held it in 14 quarters. The position peaked at $4.27M in Q2 2019. 59 funds tracked by Wall St. Rank hold ADVM as of Q4 2022.

683 Capital Management reported no remaining Adverum Biotechnologies position as of Q4 2022 after selling out during the quarter.
683 Capital Management sold 10,000 Adverum Biotechnologies shares in Q4 2022, an estimated $95K.
683 Capital Management first reported a position in Adverum Biotechnologies in Q4 2016 and held it in 14 quarters.
683 Capital Management's Adverum Biotechnologies position peaked at $4.27M in Q2 2019.
59 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2022.

Based on 683 Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.